锦波生物表示，本次增资锦波医学的资金由该公司以自有资金及新型政策性金融工具借款投入，不涉及 新股东加入，亦不存在其他股东单方面增资或者不同比例增资的情况，增资完成后锦波生物的持股比例 仍保持100.00%。 另据锦波生物介绍，锦波医学为锦波生物"人源化胶原蛋白FAST数据库与产品开发平台项目"的实施主 体。锦波生物表示，目前该项目尚在建设中，尚未产生营业收入。截至2025年9月30日，锦波医学未经 审计的资产总额约为9908.20万元，净资产约为3059.99万元。 新京报贝壳财经讯(记者黄鑫宇)12月24日，北交所上市公司山西锦波生物医药股份有限公司(即"锦波生 物"，920982.BJ)公告称，根据公司战略发展规划及业务发展需要，公司拟向全资子公司锦波医学生物 材料(北京)有限公司(即"锦波医学")增资1.65亿元，本次增资完成后，锦波医学的注册资本将由3500万元 增加至2亿元。 企查查显示，锦波医学的经营范围为化妆品生产、卫生用品和一次性使用医疗用品生产、第三类医疗器 械生产及经营等；成立于2023年1月31日，注册地位于北京市大兴区。 ...

Core Insights - As of December 24, the total margin financing and securities lending balance on the Beijing Stock Exchange reached 7.959 billion yuan, an increase of 71.38 million yuan from the previous trading day, marking a continuous increase for four consecutive trading days [1] - The stocks with the highest margin financing balances include Jinbo Biological, Shuguang Digital Innovation, and Better Energy, with latest balances of 399 million yuan, 370 million yuan, and 339 million yuan respectively [1] - A total of 182 stocks on the Beijing Stock Exchange received net margin purchases on December 24, with 44 stocks having net purchases exceeding 1 million yuan, led by Tianli Composite with a net purchase of 9.5846 million yuan [1][2] Margin Financing Overview - The margin financing balance increased for the following stocks on December 24: - Tianli Composite: 572.73 million yuan, up by 9.5846 million yuan, with a market value ratio of 0.67% [2] - Tiangong Co.: 321.16 million yuan, up by 6.5918 million yuan, with a market value ratio of 2.46% [2] - Hongyu Packaging: 254.18 million yuan, up by 6.407 million yuan, with a market value ratio of 0.83% [2] Industry Performance - The industries with the highest concentration of stocks receiving net margin purchases over 1 million yuan include machinery equipment, automotive, and basic chemicals, with 6, 5, and 4 stocks respectively [2] - On December 24, stocks with net margin purchases exceeding 1 million yuan had an average increase of 0.98%, with notable gainers including Tiangong Co. (up 16.15%), Jiahe Technology (up 9.60%), and Litong Technology (up 6.73%) [2] - The average turnover rate for stocks with net margin purchases over 1 million yuan was 4.60%, with the highest turnover rates seen in Tiangong Co. (38.53%), Xingchen Technology (21.24%), and Knight Dairy (18.00%) [2]

证券代码：920982 证券简称：锦波生物 公告编号：2025-185 山西锦波生物医药股份有限公司 关于拟向全资子公司增加注册资本的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、对外投资概述 （一）基本情况 根据公司战略发展规划及业务发展需要，公司拟向全资子公司锦波医学生 物材料（北京）有限公司（以下简称"锦波医学"）增资人民币 16,500 万元， 本次增资完成后锦波医学的注册资本由人民币 3,500 万元增加至人民币 20,000 万元。 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 根据《上市公司重大资产重组管理办法》的相关规定，本次对外投资系对 全资子公司增资，不构成重大资产重组。 （七）投资对象是否开展或拟开展私募投资活动 本次交易标的不涉及开展或拟开展私募投资活动，不是已在中国证券投资基 金业协会登记为私募基金管理人，不会将公司主营业务变更为私募基金管理业务。 （三）是否构成关联交易 本次交易不构成关联交易。 （四）决策与审议程序 公司于 2025 年 12 月 2 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 证券代码：920982 证券简称：锦波生物 公告编号：2025-184 （一）会议召开情况 1.会议召开时间：2025 年 12 月 23 日 山西锦波生物医药股份有限公司 第四届董事会第十八次会议决议公告 4.发出董事会会议通知的时间和方式：2025 年 12 月 20 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾 7.召开情况合法合规的说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事陈镔、王玲玲、阎丽明、梁桐栋、邓泽林因出差或外地办公以通讯方式 参与表决。 二、议案审议情况 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.提交股东会表决情况： 本议案无需提交股东会审议。 （二）审议通过《关于拟向全资子公司增加注 ...

证券之星消息，12月23日医疗美容板块较上一交易日下跌1.37%，爱美客领跌。当日上证指数报收于 3919.98，上涨0.07%。深证成指报收于13368.99，上涨0.27%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920982 | 锦波生物 | 249.76 | 1.33% | 8861.32 | 2.18亿 | | 000615 | *ST美谷 | 4.18 | -0.95% | 21.57万 | 9275.68万 | | 688363 | 华熙生物 | 43.48 | -1.29% | 2.47万 | 1.08亿 | | 300896 | 爱美客 | 142.29 | -1.46% | 2.80万 | 4.00亿 | | 代码 | 名称 | 主力净流入 (元) | | | 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- ...

Group 1 - The report highlights the performance of the North Exchange in 2025, indicating a significant rise in the North Index 50 to around 1400 points, with three distinct phases of market movement: rapid increase, oscillating rise, and a correction phase [2][12][15] - In the rapid increase phase (January 1 - March 11, 2025), the North Index 50 surged from 1,037.81 to 1,418.65 points, achieving a cumulative return of 36.70%, while the specialized index rose from 1,683.33 to 2,421.50 points, with a return of 43.85% [15][16] - The oscillating rise phase (April 7 - September 5, 2025) saw the North Index 50 increase from 1,044.07 to 1,647.01 points, yielding a cumulative return of 58.70%, and the specialized index from 1,759.64 to 2,806.39 points, with a return of 66.72% [16][17] Group 2 - The correction phase (September 15 - December 19, 2025) stabilized the North Index 50 and specialized index around 1400 and 2400 points, respectively, with the North Index 50 declining to 1,445.84 points and the specialized index to 2,440.21 points, resulting in cumulative returns of 39.32% and 44.96% [17][23] - The report emphasizes the performance of small-cap stocks, indicating that companies with market capitalizations of 0-20 billion, 20-40 billion, 40-80 billion, and above 80 billion had average returns of 54.08%, 38.60%, 18.26%, and 30.59%, respectively [26][31] - The report identifies that national and provincial-level "little giant" companies outperformed non-little giant firms, with average returns of 48.26%, 38.06%, and 39.19% for national, provincial, and non-little giants, respectively [27][29] Group 3 - The report highlights that national and provincial-level single champion companies achieved average returns of 59.27% compared to 39.61% for non-single champion companies [32][34] - In terms of industry performance, high-end equipment and new chemical materials sectors showed higher returns, with average returns of 50.20%, 28.67%, 48.49%, 40.43%, and 43.56% for high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, respectively [34][36] - The report also notes that companies with new productive forces, ESG attributes, high scarcity, and high dividends had average returns of 50.49%, 48.44%, 49.14%, and 57.51%, respectively, indicating a strong performance in these categories [37][43]

Investment Rating - The report assigns an "Accumulate" rating for the beauty and personal care sector, indicating a positive outlook for the industry [6]. Core Insights - The beauty and personal care sector has experienced a significant pullback since August, with leading high-growth companies' valuations returning to 20-30x, and PEG ratios mostly below 1x, suggesting the sector is expected to bottom out [3][6]. - Lin Qingxuan is set to go public, focusing on the oil-based skincare segment, with a projected doubling of performance in the first half of 2025 [3][6]. Summary by Sections Market Performance - The beauty and personal care sector saw a decline of over 15% since August, with leading companies experiencing a valuation correction to 20-30x. The sector's maximum drawdown reached 17%, with top companies seeing declines of over 30% [6][8]. - The Shenyuan Beauty Care Index recorded a maximum increase of 19% in 2025, with key growth stocks like Ruoyuchen, Shangmei, and Maogeping achieving maximum gains of 239%, 198%, and 121% respectively [6][8]. Company Highlights - Lin Qingxuan, which is set to launch its IPO, plans to issue 13.97 million shares at an offering price of 77.77 HKD per share, corresponding to a market capitalization of 10.9 billion HKD. The company has secured cornerstone investors including Fidelity and others, with total subscriptions reaching 62 million USD [6][8]. - Lin Qingxuan's revenue for the first half of 2025 is projected at 1.05 billion CNY, reflecting a year-on-year increase of 98%, with a net profit of 182 million CNY, up 110%. The company's main product, a camellia oil essence, generated 480 million CNY in revenue, marking a 176% increase [6][8]. Investment Recommendations - The report suggests a bottom-up selection of stocks with product and channel innovations, highlighting strong growth potential in the beauty and personal care sector. Recommended stocks include: 1. High-growth brands: Ruoyuchen, Shangmei, Maogeping 2. Stable fundamentals with potential for improvement: Dengkang Oral, Shanghai Jahwa, Shuiyang, Jinbo Biological, Beitaini, Marubi, Qingsong 3. Stocks expected to bottom out: Pola, Juzibio, Lafang, Runben, Meilitiantian Medical Health, Furida, Huaxi Biological [6][7].

证券之星消息，12月19日医疗美容板块较上一交易日上涨2.13%，爱美客领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 145.80 | 2.81% | 4.06万 | | 5.8716 | | 920982 | 锦波生物 | 251.98 | 1.60% | 1.33万 | | 3.31亿 | | 000615 | *ST美谷 | 4.11 | 1.48% | 7.03万 | | 2875.42万 | | 688363 | 华熙生物 | 44.18 | 1.28% | 3.23万 | | 1.43亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入（元） 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | ...

从资金流向上来看，当日医疗美容板块主力资金净流入6532.5万元，游资资金净流出1191.11万元，散户 资金净流出5341.39万元。医疗美容板块个股资金流向见下表： 证券之星消息，12月16日医疗美容板块较上一交易日上涨0.98%，爱美客领涨。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.56 | 2.02% | 4.62万 | 6.53 Z | | 688363 | 华熙生物 | 43.29 | -0.07% | 3.98万 | 1.74亿 | | 920982 | 锦波生物 | 262.15 | -0.32% | 1.66万 | 4.44 Z | | 000615 | *ST美谷 | 4.09 | -1.45% | 5.75万 | 2369.06万 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...

关于变更向不特定合格投资者公开发行股票并在北京证券交易所上市 持续督导、2025年度向特定对象发行股票保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 山西锦波生物医药股份有限公司（以下简称"公司"）于2025年12月12日收到 保荐机构中信证券股份有限公司（以下简称"中信证券"）《关于更换保荐代表人 的函》，具体情况如下： 证券代码：920982 证券简称：锦波生物 公告编号：2025-183 山西锦波生物医药股份有限公司 中信证券作为公司向不特定合格投资者公开发行股票并在北京证券交易所上市 项目及2025年度向特定对象发行股票项目的保荐机构，其中，鉴于向不特定合格投 资者公开发行股票并在北京证券交易所上市项目处于法定持续督导期间，保荐机构 尚需履行持续督导义务，持续督导保荐代表人为邓俊、姚曜；2025年度向特定对象 发行股票项目的保荐代表人为邓俊、姚曜。现因原保荐代表人姚曜工作变动原因， 不再负责公司持续督导工作及本次向特定对象发行股票的保荐工作。为保证公司持 续督导工作及本次向特定 ...